Pharmacokinetics of FSH and hCG Following Multiple Dose of Gonadotropins-IBSA.

Pharmacokinetics of Follicle-stimulating Hormone and Human Chorionic Gonadotrophin Following Multiple Daily Subcutaneous Injections of Gonadotropins-IBSA in Pituitary Down-regulated Female Subjects.

Pharmacokinetics of FSH and hCG after multiple subcutaneous injection of Gonadotropins-IBSA.

Study Overview

• Status: Completed
• Conditions: Infertility; Ovarian Stimulation
• Intervention / Treatment: Drug: Gonadotropins Subcutaneous

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Phase 1

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M1S 3V6
      • Pharma Medica Research Inc.
  • Quebec
    • Québec, Quebec, Canada, GIP 0A2
      • Syneos Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Female of childbearing potential, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), ≥18 and ≤45 years of age, with BMI >18.5 and <32.0 kg/m2 and body weight ≥45.0 kg.

2. Healthy as defined by:

   1. the absence of clinically significant illness and surgery within 4 weeks prior to dosing.
   2. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
3. Use of a COC containing at least 20 µg of ethinyl estradiol for at least 3 months prior to screening and willing to keep using the same oral contraceptive until the end of the study. The usual regimen (with hormone-free interval or continuous dosing) will be allowed until Day -1. Subjects must agree to take the COC in a continuous manner (no hormone-free interval) from Day 1 to Day 36.
4. Females who are sexually active with a non-sterile male partner (sterile male partners are defined as men vasectomized for at least 3 months prior to dosing) must be willing to use a male condom with intravaginally applied spermicide or total abstinence from heterosexual intercourse (when this is in line with the preferred and usual lifestyle of the subject) from screening and throughout the study and for 30 days after the last study drug administration.
5. Able to understand the study procedures and provide signed informed consent to participate in the study

Exclusion Criteria:

1. Any clinically significant abnormal finding at physical examination at screening.
2. Clinically significant abnormal laboratory test results or positive serology test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen and antibody at screening.
3. Positive pregnancy test or lactating subject.
4. Positive urine drug screen, urine cotinine test, or alcohol breath test.
5. Known allergic reactions to FSH, hCG, other gonadotropins, or other related drugs, or to any excipient in the formulation.
6. Clinically significant ECG abnormalities or vital signs abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
7. History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening.
8. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
9. FSH levels > 4 IU/L at admission in each period.
10. Presence of ovarian cysts > 10 mm in size or clinically significant ovarian enlargement at admission (Day 19).
11. Clinically significant history of an abnormal menstrual cycle.
12. Abnormal Pap smear prior to administration of the study drug (result is valid for 12 months).
13. History of ovarian cysts or enlargement.
14. History or presence of polycystic ovary syndrome.
15. Presence of undiagnosed vaginal and/or urinary tract bleeding.
16. History or presence of sex hormone dependent tumours of reproductive tract and accessory organs.
17. History of hypothalamus or pituitary gland tumours.
18. Personal history or strong family history (first degree relative) of coagulation disorders such as thromboembolic diseases (e.g., thrombophlebitis, pulmonary embolism or coagulation factors deficiency).
19. History of rare hereditary galactose and/or lactose intolerance (e.g., congenital lactase deficiency [CLD] or glucose-galactose malabsorption [GGM]).
20. Tattoos covering the potential study drug injection site or any skin conditions that would prevent the injection (e.g., psoriasis, major scar, etc.).

21. Use of medications for the timeframes specified below, except for the subject's prescribed COC and medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the PK profile of the study drug or subject safety (e.g., topical drug products without significant systemic absorption):

    1. depot injection or implant of any drug within 3 months prior to study drug administration;
    2. prescription medications within 14 days prior to study drug administration;
    3. any vaccines, including COVID-19 vaccine, within 14 days prior to study drug administration;
    4. over-the-counter (OTC) products and natural health products (including herbal remedies such as St. John's wort, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 7 days prior to study drug administration, with the exception of the occasional use of acetaminophen (up to 2 g daily);
22. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to dosing, administration of a biological product in the context of a clinical research study within 90 days prior to dosing, or concomitant participation in an investigational study involving no drug or device administration.
23. Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to dosing.
24. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Gonadotropins 150 IU; 150 IU daily for 7 days.	Drug: Gonadotropins Subcutaneous; Gonadotropins s.c. multiple dose
Experimental: Gonadotropins 300 IU; 300 IU daily for 7 days	Drug: Gonadotropins Subcutaneous; Gonadotropins s.c. multiple dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary PK endpoints	Day 20: AUC0-24	until 240 hours post dose.
Primary PK endpoints	Day 20:Cmax: to assess the bioavailability of the test product in terms of rate (baseline-corrected, dose-normalised Cmax) of Gonadotropins-IBSA absorption after multiple s.c. injection to healthy female subjects.	until 240 hours post dose.
Primary PK endpoints	Day 20: Tmax (Time to achieve Cmax)	until 240 hours post dose.
Primary PK endpoints	Day 26: AUC0-24	until 240 hours post dose.
Primary PK endpoints	Day 26: Cmax: to assess the bioavailability of the test product in terms of rate (baseline-corrected, dose-normalised Cmax) of Gonadotropins-IBSA absorption after multiple s.c. injection to healthy female subjects.	until 240 hours post dose.
Primary PK endpoints	Day 26: Tmax (Time to achieve Cmax)	until 240 hours post dose.
Primary PK endpoints	Accumulation potential: Rac	Through the duration of the study

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Inhibin B	Analysis of Inhibin B	until 240 hour post last dose
Estradiol (E2)	Analysis of Estradiol (E2)	until 240 hour post last dose.
Number of Follicle	Follicle growth	After seven days of treatment
Adverse events (AEs)	Percentage of subjects with any AEs	From the signature of the Informed Consent until the end of the study.
Immunogenicity	Incidence of anti-FSH antibodies be analyzed only for subjects with ADA positive results.	At pre-dose on Day 20.
Immunogenicity	Incidence of anti-FSH antibodies be analyzed only for subjects with ADA positive results.	240 hours post-last dose
Immunogenicity	Incidence of anti-FSH antibodies	576 hours post last dose
Immunogenicity	Incidence anti-hCG antibodies	At pre-dose on Day 20
Immunogenicity	Incidence anti-hCG antibodies	240 hours post-last dose and 576 hours post last dose.
Immunogenicity	Incidence anti-hCG antibodies	576 hours post last dose.
Immunogenicity	Neutralizing antibodies (NAbs)	Only for subjects with ADA positive

Collaborators and Investigators

• Sponsor: IBSA Institut Biochimique SA

Study record dates

Study Major Dates

• Study Start (Actual): October 10, 2024
• Primary Completion (Actual): August 29, 2025
• Study Completion (Actual): August 29, 2025

Study Registration Dates

• First Submitted: October 16, 2024
• First Submitted That Met QC Criteria: October 24, 2024
• First Posted (Actual): October 26, 2024

Study Record Updates

• Last Update Posted (Actual): June 5, 2026
• Last Update Submitted That Met QC Criteria: June 3, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Infertility
• Other Study ID Numbers: 23CDN-FCG09

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No